Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.3 is now shown, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 is reflected on the page. This is a technical update with no substantive changes to study data or displayed information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a dedicated Locations section featuring Colorado as a study site and updated the page revision to v3.3.3; removed the Colorado Locations and HHS Vulnerability Disclosure items (and the older Revision: v3.3.2 reference).SummaryDifference0.2%

- Check112 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.